Today: 20 May 2026
Thermo Fisher stock price holds near $619 after-hours as tariff fears slam Wall Street
21 January 2026
1 min read

Thermo Fisher stock price holds near $619 after-hours as tariff fears slam Wall Street

New York, Jan 20, 2026, 19:41 EST — After-hours

Shares of Thermo Fisher Scientific Inc (TMO) closed Tuesday up 26 cents at $619.01 and showed little movement after hours, following the 4 p.m. close. The stock traded between $607.37 and $620.75 during the session, with roughly 3.1 million shares changing hands.

The quiet shift is still notable. As January enters its second half, markets are growing more jittery over trade policy and interest rates, with Thermo Fisher emerging as a key indicator for lab spending trends.

Traders are treating it as a steady gauge for now, not a headline grabber. The upcoming earnings report is near enough to keep attention, but not imminent enough to resolve much.

The broader market took a hit. Wall Street suffered its steepest daily decline in three months after President Donald Trump warned of new tariffs on imports from several European nations. The announcement sent investors scrambling toward safer bets, triggering a clear “risk-off” mood. “Not seeing indications investors were fleeing,” noted Jamie Cox, managing partner at Harris Financial Group. Reuters

Among Thermo Fisher’s peers, the declines stood out: Danaher slipped roughly 0.7%, Agilent dropped 2.7%, and Becton Dickinson was down 1.8% at the close.

Thermo Fisher plans to report its fourth-quarter and full-year 2025 earnings ahead of the market open on Jan. 29, followed by a conference call at 8:30 a.m. ET.

Investors will focus on the usual signals: order patterns for instruments and consumables, the mood around pharma and biotech customer budgets, and the company’s outlook on demand heading into 2026. It’s the guidance—not just the quarterly results—that’s expected to drive the next move.

The downside risk is straightforward. Should the tariff fears spark a prolonged spell of volatility, or if Thermo Fisher’s guidance comes in cautious, a stock that seemed defensive on Tuesday could still get caught up in the sell-off.

Looking ahead to the next session, all eyes are on whether the tariff story maintains momentum and how the initial earnings releases impact risk appetite. For Thermo Fisher, the key date is Jan. 29 at 8:30 a.m. ET, when its next major catalyst arrives.

Stock Market Today

  • Okta (OKTA) Stock Declines Amid Market Despite Strong Earnings Outlook
    May 19, 2026, 7:32 PM EDT. Okta (OKTA) shares fell 1.68% to $74.45, underperforming the S&P 500's slight 0.02% decline. The cloud identity management firm is expected to report earnings per share (EPS) of $0.57, a 29.55% increase year-over-year, and revenue of $649.35 million, up 11.19%. Annual forecasts predict EPS of $2.61 and revenue of $2.56 billion, marking increases of 63.13% and 13.19%, respectively. Despite the recent stock drop, Okta holds a Zacks Rank #1 (Strong Buy), reflecting optimistic analyst revisions. The stock trades at a forward price-to-earnings ratio of 29.07, above the industry average of 17.59, and a PEG ratio of 1.26 compared to the industry's 1.58, indicating valuation relative to earnings growth.

Latest articles

James Hardie Drops After Warning on Housing, Even With Q4 Beat

James Hardie Drops After Warning on Housing, Even With Q4 Beat

20 May 2026
James Hardie’s U.S.-listed shares dropped 6.1% Tuesday and slid another 2.6% after hours after reporting a 35% fall in quarterly net income to $28.5 million, despite a 45% jump in net sales to $1.40 billion. The company cited weak housing demand and warned the market remains uncertain. ASX shares had not traded post-earnings; they last closed at A$26.78, up 2.9%.
SELLAS Stock Jumps as One Trial Number Puts Cancer Readout in Focus

SELLAS Stock Jumps as One Trial Number Puts Cancer Readout in Focus

20 May 2026
SELLAS Life Sciences shares rose 4.1% to $7.59 Tuesday after CEO Angelos Stergiou said its Phase 3 AML trial is two events from final analysis. The company reported $107.1 million in cash and a first-quarter net loss of $8.4 million. The REGAL trial’s main measure is overall survival. SELLAS remains blinded to results until the 80th event triggers data review.
Red Robin Shares Rise After Earnings Beat

Red Robin Shares Rise After Earnings Beat

20 May 2026
Red Robin shares surged 15.6% after hours to $4.45 Tuesday, following first-quarter revenue of $378.3 million that beat Wall Street estimates despite a 0.6% drop in comparable sales and a 1.6% decline in guest traffic. Net loss was $2.2 million, or 12 cents per share. The company reaffirmed its 2026 outlook and said refranchising talks are in final stages.
Dow Jones today: Dow drops 870 points on Trump Greenland tariff threat as volatility jumps
Previous Story

Dow Jones today: Dow drops 870 points on Trump Greenland tariff threat as volatility jumps

Chevron stock price slips as Tengiz shutdown headlines hit CVX; Turkey talks add fresh focus
Next Story

Chevron stock price slips as Tengiz shutdown headlines hit CVX; Turkey talks add fresh focus

Go toTop